A recent study showed using ultrasound and elastography of the liver could help diagnosis steatosis and fibrosis in patients with psoriasis.
“Several studies have reported that non-alcoholic fatty liver disease is more frequent in patients with psoriasis, but few have reviewed the presence of liver fibrosis in those patients,” the researchers said.
In the cross-sectional cohort, single-center study, the researchers recruited 71 patients with moderate to severe psoriasis who visited a psoriasis unit at a tertiary hospital. Liver ultrasound was used to assess the grade of liver steatosis, and transitional vibration-controlled elastography was used to measure the quantity of liver fibrosis.
Does Psoriasis Increase ESRD Risk?
How Common Is Liver Fibrosis Among Patients With Severe Psoriasis?
The maximum historical Psoriasis Area and Severity Index (PASI) average was 14.4, while the baseline PASI average at the time of the study was 2, the researchers noted.
Overall, 36% of patients met the criteria for metabolic syndrome and 52% had steatosis. Steatosis was significantly related to male sex, metabolic syndrome comorbidities, elevated aspartate transaminase/alanine transaminase enzymes, dyslipidemia, and high initial PASI, the researchers said. Moderate liver fibrosis was found in 14% of patients, with 30% found to have liver steatosis observed on ultrasound, they added.
“Elastography may be a useful tool along with ultrasound to evaluate liver disease in patients with psoriasis,” the researchers concluded.
Magdaleno-Tapial J, Valenzuela-Oñate C, Ortiz-Salvador JM, et al. Prevalence of non-alcoholic fatty liver and liver fibrosis in patients with moderate-severe psoriasis: A cross-sectional cohort study [published November 15, 2019]. Australas J Dermatol. doi:10.1111/ajd.13175